News and Announcements
OncoSil Medical CEO Presentation & AGM October 2016
- Published October 18, 2016 3:29PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th October 2016, ASX Announcement
Achievements Delivered FY16
September 2015 – Submission of CE Mark application for OncoSil™
October 2015 – OncoSil™ CE Mark application granted Fast Track review status
December 2015 – Investigational Device Exemption submitted to the FDA for OncoPac-1 clinical study
January 2016 – Chris Roberts appointed Independent Non-Executive Director
February 2016 – $10 million private placement to Regal Funds Management
March – April 2016 – Q-Submissions meeting with FDA
-Responses to CE Mark and FDA questions
May 2016 – OncoSil Medical completes hiring of senior management for the Leadership Team
June 2016 – IDE Amendment submitted to the FDA for OncoPac-1 clinical study
To view the full Presentation, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
